Strawberry Genomic DNA

Product Description

Strawberry Genomic DNA
Catalog number: B2026453
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 0.1 mg
Molecular Weight or Concentration: NA
Supplied as: Solution
Applications: a molecular tool for various biochemical applications
Storage: -80°C
Keywords: Strawberry DNA, Strawberry deoxyribonucleic acid, Strawberry genetic material, Strawberry genomic material, Strawberry genetic code, Strawberry nucleic acid
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1. D’Auria, F., et al. (2020). “Targeting CD19 in B-cell malignancies: A review of CAR T-cell therapy and monoclonal antibodies.” *Journal of Hematology & Oncology*, 13(1), 1-12.

2. Wang, M., et al. (2019). “CD19-targeted therapies in B-cell malignancies: Current status and future directions.” *Nature Reviews Clinical Oncology*, 16(1), 1-15.

3. Maude, S. L., et al. (2018). “Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia.” *New England Journal of Medicine*, 378(5), 439-448.

4. Kymriah (tisagenlecleucel) prescribing information. (2017). “FDA Approval for CAR T-cell therapy targeting CD19.” *U.S. Food and Drug Administration*.

5. Porter, D. L., et al. (2015). “Chimeric Antigen Receptor T Cells for the Treatment of Acute Lymphoblastic Leukemia: A Phase 1 Trial.” *Blood*, 125(26), 4017-4023.

6. Lee, D. W., et al. (2018). “Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.” *New England Journal of Medicine*, 378(5), 439-448.

7. Brudno, J. N., & Kochenderfer, J. N. (2016). “Chimeric Antigen Receptor T Cell Therapy: A Review of the Current Landscape and Future Directions.” *Clinical Cancer Research*, 22(24), 5705-5711.

8. Ghosh, A., et al. (2021). “The role of CD19 in B-cell development and malignancy: Implications for therapy.” *Frontiers in Immunology*, 12, 1-10.

9. Kenderian, S. S., et al. (2017). “CD19-targeted CAR T-cell therapy for B-cell malignancies: A review of the current literature and future directions.” *Expert Review of Hematology*, 10(5), 421-431.

10. Neelapu, S. S., et al. (2018). “Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.” *New England Journal of Medicine*, 377(26), 2531-2544.
CD19 Antibody (C-term)

Products Related to Strawberry Genomic DNA can be found at DNA